Europe, Middle East & Africa
Bring your biosimilar to market faster.
The race is on to bring your biosimilar to market faster. Boost your progress by asking the right questions and creating a customized approach to meet your goals.
联系我们
专家LED决策支持
导航生物仿制物监管和付款人景观是挑战，为医生提供现实的世界证据，并争夺正确的场地和患者。IQVIA可以帮助您克服这些障碍，并使用超过13个治疗领域的专业知识支持的定制方法在整个研究的生命周期中做出更好的决定。
It starts when you leverage the power of the IQVIA CORE™. This is how we use unparalleled data, transformative technology, advanced analytics, and scientific expertise to help achieve study goals and bring biosimilar drugs to market faster.
Powered by the IQVIA CORE
- Experts that have built trial designs for more than a dozen compounds over the past decade, reaching 20 unique biological targets
- Transformative technology that allows real-time access to operation-critical information to accelerate study timelines
- 无与伦比的数据来源可优化生物仿制药物开发
- Advanced analytics capabilities to identify the right sites – inclusive of established site relationships – allowing for faster start-up and accelerated patient enrollment
IQVIA Integrated Biosimilar Offerings
Customizable scope of solutions to meet your study needs
Institute Research Brief
A positive road ahead for biosimilars?
生物仿制物的轨迹发生了变化 - 并且根据当前投影，将继续在向上路径上。随着生物制剂支出的持续增加，生物仿虫市场呈现出储蓄药物的机会。
Learn more
解决方案you may be interested in
Latest Thinking
White Paper
BioSimilars.for Retinal Vascular Diseases:
Considerations for clinical trials of anti-VEGF biosimilars in a crowded landscape